Can-Fite BioPharma Ltd.

Multiple Shots On Goal: Can-Fite's Late-Stage Clinical Pipeline Hits Positive Results

This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers

Attacking Diseases On Multiple Fronts — Pharmaceutical Development Combined With Cannabis?

This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers

Attacking Diseases On Multiple Fronts — Pharmaceutical Development Combined With Cannabis?

This Biotech Company Looks To Be Targeting A New Drug To Treat NASH, The Leading Cause of Liver Transplants

Psoriasis Drug Providers Looking Over Shoulders At Upcoming Competitor?

This Biotech Company Looks To Be Targeting A New Drug To Treat NASH, The Leading Cause of Liver Transplants

Psoriasis Drug Providers Looking Over Shoulders At Upcoming Competitor?

A New Oral Therapy for Psoriasis Could Be Coming Soon

PRIOR TO PHASE III PSORIASIS DATA RELEASE CAN FITE REPORTS THAT PICLIDENOSON DESTROYS PATHOLOGICAL SKIN CELLS IN VITRO

Can-Fite BioPharma Ltd. Recent News

Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference

Dawson James - Can-Fite (CANF) Buy Rated - Expected Milestones

Can-Fite in a letter to shareholders outlined the milestones ahead for the year. Click here for the full report COMFORT-Plaque Psoriasis: Topline Phase 3 Psoriasis Data Expected Q122

CAN-FITE ISSUES LETTER TO SHAREHOLDERS

Q1 2022: Psoriasis Phase III Data & Commencement of Enrollment in Phase IIb NASH H1 2022: Commencement of Enrollment in Phase III Liver Cancer

FOLLOWING COMPLETE CLEARANCE OF CANCER LESIONS IN ADVANCED LIVER CANCER PATIENT, CAN-FITE IS FILING PATENT APPLICATIONS FOR THE TREATMENT OF VARIOUS ADVANCED SOLID TUMORS

Namodenoson Headed into Pivotal Phase III Liver Cancer Study

Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Piclidenoson From Can-Fite Biopharma Shows New, Promising Developments For Psoriasis Treatment

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Earnings Roundup: iAnthus, Can-Fite, Organigram, Bluma Wellness, Auxly

iAnthus Touts 82% YoY Revenue Growth, Names Interim COO